EN DE

RadNet Inc (RDNT) Fair Value & Analysis

Healthcare · US · Market cap $5.0B · ISIN US7504911022

What is RadNet Inc really worth?

RI RadNet Inc logo RadNet Inc RDNT · US
Price$74.62
Fair Value$5.75
Upside−92.3% ⚠
Quality27/100

Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.

Below-average quality, and trading another 1,197% above our fair value of $5.75.

Watch RadNet Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Moderate debt · generates free cash flow

Risks

!Mixed Growth (revenue 5y +13.7 %/yr)
!Loss-making · -0.7% net margin
!Trails peers (4/14)
!Narrow moat 22/100
!Evidence only low, so the estimate is less certain
!Weak on past: 7 out of 100
!Weak on dividend: 3 out of 100
Evidence: Low Range $5.75 – $10.66

Fair value as of: Aug 14, 2026

From 15 valuation models · updated 22 days ago

Share price +7.8% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits above even our optimistic bull case ($10.66). The favourable scenario is already priced in.
  • Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
  • A fairly wide model range ($5.75 to $10.66) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

$86.38 $15.17 Fair Value $5.75 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 14, 2026.

How to read this chart

60‑month range $15.17 – $86.38 · fair‑value band $5.75 – $10.66 · the $74.62 price screens above the $5.75 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Aug 14, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

RadNet Inc (RDNT) currently trades at $74.62, while our model-based Fair Value estimate is $5.75, implying the stock looks roughly 1,197.0% overvalued today. The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of $20.04 per share, and 0 of the 15 models we run sit above the $74.62 price. Bear case: the Dividend Discount group reads lowest at $1.20, and 15 of the 15 models stay below the price. Evidence for this calculation is low.

Over the trailing twelve months, RadNet Inc generated revenue of $2.1B at a net margin of −0.7%. Revenue grew 22.1% year over year. It earns a return on equity of 1.8%. Net debt stands at $1.1B. Fundamentals as of Aug 14, 2026

Our scenario range runs from $5.75 (bear case) to $10.66 (bull case); at $74.62, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 13% below its 52-week high and 47% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −54% fair-value upside, at −92%, RDNT screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Note: the current price implies far more future growth than the conservative anchors of our models allow (base growth is deliberately capped, we do not regard such extreme rates as sustainable). Our models are not designed for expectations this high; that is why the individual models scatter extremely ($1.20 to $42.79). Read the values as a conservative anchor, not as a price target.
Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF $9.61 $20.04 $37.61 76
Growth DCF $9.46 $18.87 $34.07 75
EPV $5.00 $6.39 $7.58 74
All 15 models by family
DCF Models
FCF DCF $9.61 $20.04 $37.61 76
5Y Revenue Exit $7.59 $15.84 $26.99 70
5Y EBITDA Exit $20.61 $42.79 $71.03 72
10Y Revenue Exit $7.82 $15.80 $27.96 64
10Y EBITDA Exit $16.62 $35.15 $64.13 65
Earnings-Based
EPV $5.00 $6.39 $7.58 74
Dividend Discount
Gordon GGM $0.7000 $1.39 $2.11 67
DDM Multi-Stage $0.7000 $1.20 $1.47 67
Multiples
EV/EBIT $10.94 $15.85 $20.76 65
EV/EBITDA $28.66 $39.47 $50.28 67
EV/Revenue $6.73 $11.23 $15.73 52
Asset-Based
NCAV (Graham) $6.93 $9.29 $13.86 54
Growth DCF
Growth DCF $9.46 $18.87 $34.07 75
Rev-Margin DCF $7.59 $15.67 $26.15 70
Economic Profit
ROIC Compounder $5.00 $6.39 $7.58 72

Widest divergence: DCF Models ($20.04) versus Dividend Discount ($1.20). Highest evidence: FCF DCF (76).

Notify me when RDNT reaches fair value

Put RDNT on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/S ratio 2.31 TTM
EPS (TTM) $−0.1700
Dividend yield 0.1%
Net margin −0.9% FY2025
Return on equity 1.8% TTM
Return on assets (EBIT) 3.0% avg 5y
More key figures
Profitability
Operating margin −2.9% TTM
Growth
Revenue (TTM) $2.1B TTM
Revenue growth (YoY) +22.1% 3y avg +12.6%
EPS growth (YoY) +75.0%
Balance sheet & cash flow
Free cash flow $85.6M FY2025
Net debt $1.1B FY2025 · ≈ 12.8 yrs of FCF

Figures from reported company fundamentals · as of Aug 14, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 27/100

Of which business quality 30 · Market factors (momentum, volatility) 51

Profitability 15
Margins and returns on capital today
Quality Growth 34
Are margins and returns improving?
Cashflow 29
Earnings quality: real cash, not paper profit
Fin. Strength 41
Balance sheet, leverage, solvency risk
Investment 25
Disciplined investing over empire-building
Low Volatility 37
Calm price path (market factor)
Momentum 60
Price trend over the last 3–12 months (market factor)
52W Momentum 54
Distance to the 52-week high (market factor)
Net Issuance 37
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health.

Full company description

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretations of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

RadNet Inc reported revenue of $2.0B in FY2025 versus $1.3B in FY2021, a compound +11.6%/yr. Reported net income was −$18.7M in FY2025.

Growth Quality 62/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
$2.0B
Latest YoY
+11.5%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+12.6%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+13.7%
Avg. revenue growth/yr (30Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+13.5%
Value creation/yr ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Revenue +11.6%/yr
FY21 $1.3B
FY22 $1.4B
FY23 $1.6B
FY24 $1.8B
FY25 $2.0B
Net income
FY21 $24.7M
FY22 $10.7M
FY23 $3.0M
FY24 $2.8M
FY25 −$18.7M

RDNT screens 1,197% overvalued. Compare with Thermo Fisher Scientific Inc →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

RadNet Inc · Fair Value
$5.75 −1197%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "RadNet Inc Fair Value". https://www.fairvalue-calculator.com/stock/RDNT

Peer Group

Diagnostics & Research · 130 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 27 · Bottom 25%
Fair Value upside −92% · Bottom 25%
Return on equity (TTM) 2% · Below median
Return on assets 2% · Above median
Net margin (TTM) −1% · Below median
Operating margin (TTM) −3% · Below median
Revenue growth 22% · Top 25%
Dividend yield (TTM) 0.1% · Bottom 25%
Debt / equity 0.98× · Higher than 75% of peers

Valuation Multiples vs Diagnostics & Research median · lower = cheaper

P/B 4.54× · Pricier than 75% of peers
P/S (TTM) 2.31× · Cheaper than median
P/FCF 57.9× · Pricier than 75% of peers
EV/EBITDA 20.8× · Pricier than median
PEG 0.96× · Cheaper than 75% of peers

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 0
FUTURE100 · sector 30
PAST7 · sector 12
HEALTH51 · sector 96
DIVIDEND3 · sector 20

VALUE 0: the price sits above our fair-value range.

Insider activity: 46/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 14, 2026).

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $630.70 $308.19 −51%
Danaher Corporation DHR $215.68 $103.88 −52%
WuXi AppTec Co 2359 HK$189.30 HK$150.16 −21%
Lonza Group LONN CHF 576.60 CHF 259.80 −55%
IDEXX Laboratories, Inc IDXX $556.69 $255.77 −54%
Agilent Technologies, Inc A $149.93 $61.53 −59%
Waters Corporation WAT $416.15 $121.96 −71%
IQVIA Holdings IQV $236.66 $132.17 −44%
Illumina, Inc ILMN $215.59 $95.51 −56%
Mettler-Toledo International Inc MTD $1,419 $615.78 −57%

Compare RadNet Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is RadNet Inc (RDNT) overvalued or undervalued?
As of Aug 14, 2026, our model estimates a fair value of $5.75 versus a price of $74.62, about −92% upside (overvalued).
What is the fair value of RDNT?
Our model-based fair value for RadNet Inc is $5.75 (as of Aug 14, 2026), built from audited fundamentals. The current price: $74.62.
What is the quality score of RDNT?
RadNet Inc has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of RadNet Inc (RDNT)?
RadNet Inc reported trailing-twelve-month revenue of about $2.1B (latest available figure, as of Aug 14, 2026).
What is the net profit margin of RDNT?
The net profit margin of RadNet Inc is about −0.7%, meaning it is currently running at a net loss. Based on the latest reported figures.
Does RadNet Inc pay a dividend?
RadNet Inc currently shows a dividend yield of about 0.15% relative to its recent price (as of Aug 14, 2026).
Free · no account needed

Watch RadNet Inc in the live analysis

One click puts RadNet Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.